Mesenchymal Cell News Volume 4.04 | Jan 31 2012

    0
    18

    Mesenchymal Cell News 4.04, January 31, 2012

         In this issue: Publications Industry News | Policy News | Events | Jobs 
    Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter

    TOP STORY
    Adipose Tissue-Derived Stem Cell-Seeded Small Intestinal Submucosa for Tunica Albuginea Grafting and Reconstruction
    The aim of this rat study was to assess the feasibility of seeding adipose tissue-derived stem cells onto small intestinal submucosa grafts for tunica albuginea reconstruction. [Proc Natl Acad Sci USA]
    Abstract | Press Release

    Got Paper? Get StemLab™. Schedule Your Demo.

    PUBLICATIONS (Ranked by Impact Factor of the Journal)

    Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) Enhances Engraftment and Angiogenesis of Mesenchymal Stem Cells in Diabetic Hindlimb Ischemia
    To examine whether the peroxisome PGC-1α could enhance the engraftment and angiogenesis of mesenchymal stem cells (MSCs) in diabetic hindlimb ischemia, researchers engineered the overexpression of PGC-1α within MSCs using an adenoviral vector encoding green fluorescent protein and PGC-1α, and then tested the survivability and angiogenesis of MSCs in vitro and in vivo. [Diabetes] Abstract

    High Glucose via NOX-Dependent ROS Generation and AKT Activity Promotes Adipose-Derived Stem Cell De-Differentiation
    Researchers investigated whether high glucose-dependent NADPH-oxidase (NOX)-mediated reactive oxygen species (ROS) generation is involved in self-renewal of visceral adipose tissue-derived stem cells. [Stem Cells Dev] Abstract

    Additive Effects of Sonic Hedgehog and Nell-1 Signaling in Osteogenic versus Adipogenic Differentiation of Human Adipose-Derived Stromal Cells
    In the present study, researchers assayed the potential additive effects of the biologically active N-terminus of Sonic Hedgehog and NELL-1 protein on osteogenic and adipogenic differentiation of human primary adipose-derived stromal cell. [Stem Cells Dev] Abstract

    Quantification of MSCs Involved in Wound Healing: Use of SIS to Transfer MSCs to Wound Site and Quantification of MSCs Involved in Skin Wound Healing
    This study traced mesenchymal stem cells (MSCs) participating in wound healing by using small intestinal submucosa (SIS) as a cell carrier, identified their moving path and calculated the number of MSCs involved in wound healing. [J Tissue Eng Regen Med] Abstract

    Isolation, Characterization and Differentiation of Mesenchymal Stem Cells (MSCs) from Amniotic Fluid, Cord Blood and Wharton’s Jelly in the Horse
    Researchers’ findings suggest that equine MSCs from amniotic fluid, umbilical cord blood and Wharton’s jelly appeared to be a readily obtainable and highly proliferative cell lines from an uninvasive source that may represent a good model system for stem cell biology and cellular therapy applications in horses. [Reproduction] Abstract

    Scale-Up of MSC under Hypoxic Conditions for Allogeneic Transplantation and Enhancing Bony Regeneration in a Rabbit Calvarial Defect Model
    To realize the therapeutic potential of mesenchymal stem cells (MSCs), researchers aimed to develop a method for isolating and expanding New Zealand rabbit MSCs in a great scale. [J Orthop Res] Abstract

    Adipose-Derived Mesenchymal Stromal Cells from Genetically Modified Pigs: Immunogenicity and Immune Modulatory Properties
    Researchers suggest that genetically modified pig adipose-derived mesenchymal stromal cells function across a xenogeneic barrier and may have a role in cellular xenotransplantation. [Cytotherapy]
    Abstract

    Overexpression of GDF5 through an Adenovirus Vector Stimulates Osteogenesis of Human Mesenchymal Stem Cells In Vitro and In Vivo
    In this study, the aim was to investigate the potential of growth and differentiation factor-5 (GDF5) to genetically manipulate human mesenchymal stem cells for bone regeneration. [Cells Tissues Organs] Abstract

    Watch the Video: Obtain Functional MSCs Xeno-Free with MesenCult-XF

    INDUSTRY NEWS

    Ontario’s First Cardiac Stem Cell Transplant Performed Last Week at the Peter Munk Cardiac Centre
    As part of the ongoing IMPACT-CABG clinical trial to treat advanced heart failure, physicians at the Peter Munk Cardiac Centre performed the first cardiac stem cell transplant in Ontario using stem cells derived from the patient’s own bone marrow, isolated completely within the operating room, and implanted into the heart at the time of coronary bypass surgery. [University Health Network] Press Release

    Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase II Trial for Acute Myocardial Infarction
    Amorcyte, LLC, a NeoStem, Inc. company announced the enrollment of the first patient in the Amorcyte PreSERVE Phase II trial for acute myocardial infarction. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous bone marrow derived cell therapy enriched for CD34+ cells. [NeoStem, Inc.]
    Press Release

    Creighton to Explore Usage of Adult Stem Cells to Improve Angioplasty Results
    A Creighton University School of Medicine researcher has received a $3.3 million, five-year grant from the National Institutes of Health to study what role adult stem cells might play in repairing damaged coronary arteries, a complication that often occurs in patients after they undergo angioplasty and stenting. [Creighton University] Press Release

    Cytori Receives Approval from FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
    Cytori Therapeutics has received an IDE approval from the U.S. Food and Drug Administration (FDA) to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells to treat a form of coronary heart disease, chronic myocardial ischemia. [Cytori Therapeutics, Inc.] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW Cell Society – 2nd Annual Clinical Meeting
    February 17-18, 2012
    San Diego, United States

    NEW The Annual Hilton Head Workshop: Regenerative Medicine – Harnessing Biology for Regeneration
    March 14-17, 2012
    Hilton Head Island, United States

    Visit our events page to see a complete list of events in the mesenchymal cell community.

    JOB OPPORTUNITIES

    Research and Development Technologist, hPSC Media (STEMCELL Technologies)

    Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

    Scientific Marketing Communications Specialist (STEMCELL Technologies)

    Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

    Business Analyst – Product Management (STEMSOFT Software)

    Postdoctoral Positions – Stem Cell Biology (Columbia University)

    PhD Position – Mechanobiology (University College Dublin)

    Research Associates/Scientist/Senior Scientist – Stem Cell Research (Advanced Cell Technology) 

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Mesenchymal Cell News: Archives | Events | Contact Us